Sernova Biotherapeutics Inc.

Mississauga, A6 · Biotech · Public

Cell therapy device and regenerative medicine system for correcting type 1 diabetes

Claim this profile

Follows are private to you and power your alerts

Updated · sernova.com

Sector
Biotech
Headquarters
Mississauga, A6
Latest Form D
$345K, Feb 2026
Total capital
$345K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$345K
1 Form D · last Feb 2026
9 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
1 pending · first 2025
Rank in peer group#11 of 32

Capital timeline

2026FEDERAL ↑EQUITY ↓Cumulative $345K1st Form D$345K
2026FEDERAL ↑EQUITY ↓Cumulative $345K1st Form D$345K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$345K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 32 peers

Line = median

Biotech · Device

  • Granted patents#11 · top 34%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Bernd MuehlenwegDirectorNamed in SEC Form D filings
  • David BurkeExecutive OfficerNamed in SEC Form D filings
  • David PatersonDirectorNamed in SEC Form D filings
  • James ParsonsExecutive OfficerNamed in SEC Form D filings
  • John BrooksDirectorNamed in SEC Form D filings
  • Jonathan RigbyExecutive Officer, DirectorNamed in SEC Form D filings
Show all 9 people
  • Marylyn RigbyExecutive OfficerNamed in SEC Form D filings
  • Steven SanghaDirectorNamed in SEC Form D filings
  • Tanya LewisDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .